Why the study?
Do baseline plasminogen activator inhibitor (PAI) levels correlate with reperfusion success and clinical outcomes in patients receiving rt-PA for acute myocardial infarction?
Do baseline plasminogen activator inhibitor (PAI) levels correlate with reperfusion success and clinical outcomes in patients receiving rt-PA for acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
High baseline plasma PAI-1 levels may be detrimental to early reperfusion with t-PA in acute myocardial infarction, but do not appear to influence long-term clinical outcomes.
Baseline plasminogen activator inhibitor (PAI) levels were examined for their influence on the responses to thrombolysis with recombinant tissue plasminogen activator (rt-PA) administered for acute myocardial infarction during the Thrombolysis and Myocardial Infarction (TAMI)-I study. Baseline PAI activity was 19 +/- 21 IU/ml (normal less than 5 IU/ml) and baseline PAI-1 antigen 54 +/- 53 ng/ml (normal 27 +/- 16 ng/ml), confirming previous findings of elevated PAI levels during acute myocardial infarction. Among clinical outcomes, lower PAI-1 antigen levels correlated weakly with greater patency at the 90 min angiogram. Thus, high baseline plasma PAI-1 levels may be detrimental to reperfusion with t-PA. There was no correlation with other major in-hospital clinical outcomes including reocclusion at the 7-10 day angiogram, survival to discharge, or bleeding. During the follow up period of 2.0 +/- 0.4 years, no relationship between baseline PAI levels and post-discharge reinfarction was observed.
No takes yet. Share an insight, caveat, or question.
Sane et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: